Comparison of vitamin D hydroxylation activities of rat CYP2J3 and human CYP2J2

被引:0
|
作者
Ohyama, Y [1 ]
Aiba, I [1 ]
Yamasaki, T [1 ]
Terato, H [1 ]
Ide, H [1 ]
机构
[1] Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima, Japan
来源
Proceedings of the 14th International Conference on Cytochromes P450: Biochemistry, Biophysics, and Bioinformatics | 2005年
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant rat CYP2J3 and human CYP2J2 were successfully expressed in the E. coli expression system by co-expression of chaperone proteins. Purified proteins were applied to analysis of catalytic activities toward vitamin D compounds using a reconstituting system containing NADPH-P450 reductase. The CYP2J2 showed significant but about 10 times lower 25-hydroxylation activities than CYP2J3 toward vitamin D-3 and 1 alpha-OH-D-3. Interestingly, CYP2J2 prefers vitamin D-2 to vitamin D-3 as a substrate, whereas CYP2J3 did vitamin D-3 to vitamin D-2, The results suggest involvement of CYP2J subfamily proteins in vitamin D activation through 25-hydroxylation reaction, although they showed distinct preferences and activities toward vitamin D compounds.
引用
收藏
页码:105 / 108
页数:4
相关论文
共 50 条
  • [31] Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal Microsomes
    Hashizume, T
    Imaoka, S
    Mise, M
    Terauchi, Y
    Fujii, T
    Miyazaki, H
    Kamataki, T
    Funae, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (01): : 298 - 304
  • [32] CHARACTERIZATION OF ANTIHYPERTENSIVE DRUGS AS POTENT INHIBITORS OF CYP2J2
    Yamaori, Satoshi
    Ikemura, Noriaki
    Kobayashi, Chinatsu
    Kamijo, Shinobu
    Ohmori, Shigeru
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S46 - S46
  • [33] Ophiopogonin D alleviates cardiac hypertrophy in rat by upregulating CYP2J3 in vitro and suppressing inflammation in vivo
    Wang, Yuan
    Huang, Xiaoyan
    Ma, Zengchun
    Wang, Yuguang
    Chen, Xiangmei
    Gao, Yue
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 503 (02) : 1011 - 1019
  • [34] Terfenadone is a strong inhibitor of CYP2J2 present in the human liver and intestinal microsomes
    Lee, Eunyoung
    Kim, Ju-Hyun
    Shon, Jong Cheol
    Wu, Zhexue
    Kim, Hyun Ji
    Gim, Minsik
    Lee, Taeho
    Liu, Kwang-Hyeon
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (03) : 159 - 163
  • [35] Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases
    Aiba, Isamu
    Yamasaki, Tomoaki
    Shinki, Toshimasa
    Izumi, Shunsuke
    Yamamoto, Keiko
    Yamada, Sachiko
    Terato, Hiroaki
    Ide, Hiroshi
    Ohyama, Yoshihiko
    STEROIDS, 2006, 71 (10) : 849 - 856
  • [36] Cardiomyocyte-specific CYP2J2 and its therapeutic implications
    Valencia, Robert
    Bassiouni, Wesam
    Darwesh, Ahmed M.
    Bapuji, Raj
    Seubert, John M.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (7-8) : 423 - 439
  • [37] Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo
    Kaspera, Ruediger
    Kirby, Brian J.
    Sahele, Tariku
    Collier, Ann C.
    Kharasch, Evan D.
    Unadkat, Jashvant D.
    Totah, Rheem A.
    BIOCHEMICAL PHARMACOLOGY, 2014, 91 (01) : 109 - 118
  • [38] The Cardiotoxic and Cardioprotective Potential of Cytochrome P450 2J2 (CYP2J2)
    Arnold, William R.
    Baylon, Javier
    Tajkhorshid, Emad
    Das, Aditi
    FASEB JOURNAL, 2017, 31
  • [39] CYP2J2 metabolizes domperidone in guinea pig hearts.
    Michaud, V
    Massé, R
    Turgeon, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P75 - P75
  • [40] CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design
    Das, Aditi
    Weigle, Austin T.
    Arnold, William R.
    Kim, Justin S.
    Carnevale, Lauren N.
    Huff, Hannah C.
    PHARMACOLOGY & THERAPEUTICS, 2020, 215